T3 Short Dental Implants for Toothless Jaw
(Magnolia Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial excludes patients who are currently using non-steroidal anti-inflammatory drugs, bisphosphonates, or corticosteroid treatments, so you may need to stop these medications to participate.
What data supports the effectiveness of the T3 Short Dental Implant System treatment?
Research shows that short dental implants, like the T3 Short Dental Implant System, are effective in areas with limited bone height, maintaining bone stability and having high success rates over time. Studies indicate that these implants can be a reliable option for patients with severe bone loss in the jaw, providing stable support for dental restorations.12345
Is the T3 Short Dental Implant System safe for use in humans?
Research shows that short dental implants, including those similar to the T3 Short Dental Implant System, generally have a high success rate and are considered safe. Studies found that these implants maintain bone stability and have a success rate of about 95.8% over three years, with no significant issues like pain or infection reported.35678
How is the T3 Short Dental Implant System treatment different from other treatments for toothless jaws?
The T3 Short Dental Implant System is unique because it uses short implants that can be placed in areas with limited bone volume, avoiding the need for complex bone augmentation surgeries. This approach reduces treatment time, cost, and recovery, making it suitable for patients who cannot undergo extensive surgical procedures.39101112
What is the purpose of this trial?
This clinical study will evaluate the safety and performance of the T3 short dental implant when placed in the posterior maxilla and mandible.
Research Team
Hai Bo Wen, PhD
Principal Investigator
ZimVie
Eligibility Criteria
Adults with missing teeth in the back of their mouth who can undergo standard dental procedures. They must have enough bone height and gum tissue for implants, not smoke heavily, and not be on certain medications like anti-inflammatories or steroids. Pregnant individuals or those planning pregnancy soon cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the T3 short implant or the T3 standard length implant in the posterior maxilla and mandible
Prosthetic Work Completion
All prosthetic work must be completed following implant placement surgery
Follow-up
Participants are monitored for implant integration, survival, and crestal bone regression
Treatment Details
Interventions
- T3 Short Dental Implant System
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business
ZimVie
Lead Sponsor